| 1. Northrup C. Women's
Bodies; Women's Wisdom, New York, NY Bantam Books: 1994.
2. Whitaker J. Natural Hormone Replacement. Potomac,
Md: Phillips Publishing, Inc; 1997
3. Wright JV Morgenthaler J. Natural Hormone Replacement.
Petaluma, Calif: Smart Publications; 1997.
4. Lee JR. Natural Progesterone. The Multiple Roles
of a Remarkable Hormone. Sebastopol, Calif: BLL Publishing: 1993.
5. Vliet, EL. Screaming To Be Heard. New York, NY:
M. Evans and Company, Inc: 1995.
6. Love S. Dr. Susan Love's Hormone Book. New York,
NY: Random House; 1997.
7. Lee JR. What Your Doctor May Not Tell You About
Menopause. New York, NY: Warner Books; 1996.
8. The Writing Group for the PEPI Trial. Effects
of estrogen or estrogen/progestin regimens on heart disease risk
factors in postmenopausal women. JAMA. 1995: 273:199-208.
9. Prior JC. Progesterone as a bone-trophic hormone.
Endocr Rev. 1990;11:386-398.
10. Hargrove JT, Maxson WS, Wentz AC, Burnett LS.
Menopausal hormone replacement therapy with continuous daily oral
micronized estradiol and progesterone. Obstet Gynecol. 1989:73:
606-612.
11. Maxson WS. The use of progesterone in the treatment
of PMS. Clin Obstet Gynecol. 1987:30:465-477.
12. Dalton K. The Premenstrual Syndrome and Progesterone
Therapy. London, England: William Heinemann; 1984.
13. Vercellini P, De Giorgi O, Oldani S, et al.
Depot medroxyprogesterone acetate versus an oral contraceptive combined
with very-low-dose danazol for long-term treatment of pelvic pain
associated with endometriosis. Am J Obstet Gynecol. 1996;175:396-401.
14. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional
medicine in the United States. Prevalence, costs, and patterns of
use. N Engl J Med. 1993;328:246-252.
15. Williams CL, Stancel GM. Estrogens and progestins.
In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman &
Gilman's The Pharmacologic Basis of Therapeutics. 9th ed. New York,
NY: McGraw-Hill 1996:1411-1440.
16. Yen SSC. Endocrine-metabolic alterations in
pregnancy. In: Yen SSC, Jaffe RB, eds. Reproductive Endocrinology.
Philadelphia, Pa: WB Saunders Co; 1991:936-981.
17. Pharmacology of the endocrine system and related
drugs. Progesterone, pro-gestational drugs, and antifertility agents.
In: Tausk M, ed. International Encyclopedia of Pharmacology and
Therapeutics.New York, NY Pergamon Press; 1971.
18. Chang KJ Lee TT, Linares-Cruz G, et al. Influences
of percutaneous administration of estradiol and progesterone on
human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63:785-791
19. Hargrove JT, Osteen KG. An alternative method
of hormone replacement therapy using the natural sex steroids. Infertil
Reprod Med Clin. 1995;6:653-674.
20. Bayliss DA, Millhorn DE. Central neural mechanisms
of progesterone action. Application to the respiratory system. J
Appl Physiol. 1992:73:393-404.
21. Rudel HW, Kincl FA. The toxicity of progesterone.
In: Tausk M, ed. International Encyclopedia of Pharmacology
and Therapeutics. New York, NY: Pergamon Press; 1971:405-409.
22. Ferre F, Uzan M, Janssens Y, et al. Oral administration
of micronized natural progesterone in late human pregnancy. Effects
on progesterone and estrogen concentrations in the plasma, placenta,
and myometrium. Am J Obstet Gynecol. 1984:148:26-34.
23. Maxson WS, Hargrove JT. Bioavailability of oral
micronized progesterone. Fer til Steril. 1985:44:622-626.
24. Sitruk-Ware R, Bricaire C, DeLignieres B, et
al. Oral Micronized progesterone. Bioavailability pharmacokinetics,
pharmacological and therapeutic implications—A Review, Contraception.
1987; 36:373-402.
25.Grady D, Rubin SM, Petitti DB, et al. Hormone
therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med. 1992;117: 1016-1037.
26. Gambrell RD, Jr. The prevention of endometrial
cancer in postmenopausal women with progestogens. Maturitas. 1978;
1: 107-112.
27. Sitruk-Ware R. Transdermal delivery of steroids.
Contraception. 1989:39:1-20.
28. Mauvais-Jarvis P, Baudot N, Bercovici JP. In
vivo studies on progesterone metabolism by human skin. J Clin Endocrinol
Metab. 1969;29:1580-1585.
29. Nillius SJ, Johansson ED. Plasma levels of progesterone
after vaginal, rectal, or intramuscular administration of progesterone.
Am J Obstet Gynecol. 1971; 110:470-477.
30. Myers ER, Sondheimer SJ, Freeman EW et al. Serum
progesterone levels following vaginal administration of progesterone
during the luteal phase. Ferill Steril. 1987;47:71-75.
31. Kimzey LM, Gumowski J, Merriam GR, et al. Absorption
of micronized progesterone from a nonliquefying vaginal cream. Fertil
Steril. 199 1;56:995-996.
32. Fanchin R, De Ziegler D, Bergeron C, et al.
Transvaginal administration of progesterone. Obstet Gynecol. 1997;90:
396-401.
33. Casanas-Roux F, Nisolle M, Marbaix E, et al.
Morphometric, immunohistological and three-dimensional evaluation
of the endometrium of menopausal women treated by oestrogen and
Crinone, a new slow-release vaginal progesterone. Hum Reprod. 1996;
11:357-363.
34. Pitha J, Harman SM, Michel ME. Hydrophilic cyclodextrin
derivatives enable effective oral administration of steroidal hormones.
J Pharm Sci. 1986; 75:165-167.
35. Antoniou G, Kalogirou D, Karakitsos P, et al.
Transdermal estrogen with a levonorgestrel- releasing intrauterine
device for climacteric complaints versus estradiol-releasing vaginal
ring with a vaginal progesterone suppository. Clinical and endometrial
responses. Maturitas. 1997;26:103-111.
36. Suvanto-Luukkonen E, Sundstrom H, Penttinen
J, et al. Percutaneous estradiol gel with an intrauterine levonorgestrel
releasing device or natural progesterone in hormone replacement
therapy. Maturitas. 1997;26:211-217.
37. Sitruk-Ware R, Utian WH, eds. The Menopause
and Hormonal Replacement Therapy. New York, NY: Marcel Dekker,
Inc; 1991.
38. van Keep PA, Utian WH, Vermeulen A, eds. The
Controversial Climacteric. Lancaster, England: MTP Press Limited;
1981.
39. Lee JR. Is natural progesterone the missing
link in osteoporosis prevention and treatment? Med Hypotheses. 1991;
35:316-318.
40. Lee JR. Osteoporosis reversal with transdermal
progesterone. Lancet. 1990;336:1327.
41. Lindsay R, Tohme JF. Estrogen treatment of patients
with established postmenopausal osteoporosis Obstet Gynecol. 1990;76:290-295.
42. Riggs BL, Melton LJ III. Involutional osteoporosis.
N Engl J Med. 1986;314: 1676-1686.
43. Utian WH. Menopause in Modern Perspective. New
York, NY Appleton-Century-Crofts; 1980.
44. Dalton K. The Premenstrual Syndrome.Springfield,
Ill: Charles C. Thomas; 1964.
45. Dalton K. Trial of progesterone vaginal suppositories
in the treatment of premenstrual syndrome. Am J Obstet Gynecol.
1987;156:1555-1556.
46. Freeman E, Rickels K, Sondheimer SJ, Polansky
M. Ineffectiveness of progesterone suppository treatment for premenstrual
syndrome. JAMA. 1990:264: 349-353.
47. Magill PJ. Investigation of the efficacy of
progesterone pessaries in the relief of symptoms of premenstrual
syndrome. Br J Gen Pract. 1995;45:589-593.
48. Brown CS, Freeman EW, Ling FW. An update on
the treatment of premenstrual syndrome. Am J. Managed Care. 1998;
4:266-274.
49. Dennerstein L, Spencer-Gardner C, Gotts G, et
al. Progesterone and the premenstrual syndrome. A double blind crossover
trial. Br Med J. 1985:290: 1617-1621.
50. Gold JH, Severino SK, eds. Premenstrual dysphorias:
myths and realities. Washington, DC: American Psychiatric Press;
1994.
51. George MS, Guidotti A, Rubinow D, et al. CSF
neuroactive steroids in affective disorders. Pregnenolone, progesterone,
and DBI. Biol Psychiatry. 1994;35: 775-780.
52. Physician' Desk Reference. Montvale, NJ: Medical
Economics; 1998:822, 924, 2261,2263,3118,3123.
53. Miller JB. Relief of premenstrual symptoms,
dysmenorrhea and contraceptive tablet intolerance. A preliminary
report. J Med Assoc State Ala. 1974:44:57-60.
54. Mabray CR, Burditt ML, Martin TL, et al. Treatment
of common gynecologic-endocrinologic symptoms by allergy management
procedures. Obstet Gynecol. 1982;59:560-564.
55. Beynon HL, Garbett ND, Barnes PJ. Severe premenstrual
exacerbations of asthma. Effect of intramuscular progesterone. Lancet.
1988:2:370-372.
56. Sitruk-Ware R, Seradour B, Lafaye C. Treatment
of benign breast diseases by progesterone applied topically. In:
Mauvais-Jarvis P, Vickers CFH, Wepierre J, eds. Percutaneous Absorption
of Steroids. New York, NY: Academic Press; 1980:219-229.
57. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast
cancer incidence in women with a history of progesterone deficiency.
Am J Epidemiol 1981; 114:209-217. |
